PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.48
−3.48%Sep 9, 2026, 15:48 UTC
Phathom Pharmaceuticals presented at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, highlighting rapid revenue growth and its first quarterly operating profit excluding stock-based compensation.
Source:Jul 31, 2026, 14:07 UTC
SueWallSt notified investors of potential securities claims involving Phathom Pharmaceuticals, related to the company's full-year revenue guidance.
Source:Jul 30, 2026, 10:59 UTC
Phathom Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.
Source:Jun 23, 2026, 11:59 UTC
Phathom Pharmaceuticals completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA (vonoprazan) for eosinophilic esophagitis.
Source: